G01N 2800/2821
Alzheimer
G01N2800/2821 (Alzheimer) appears on 970 US grants and 2,011 published applications in this corpus.
Search patents in G01N- Granted patents
- 970
- Published applications
- 2,011
- Assignees
- 946
- Inventors
- 3,455
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 2 | 0 |
| 1990 | 2 | 0 |
| 1991 | 3 | 0 |
| 1992 | 3 | 0 |
| 1993 | 14 | 0 |
| 1994 | 1 | 0 |
| 1995 | 6 | 0 |
| 1996 | 8 | 0 |
| 1997 | 12 | 0 |
| 1998 | 15 | 0 |
| 1999 | 16 | 0 |
| 2000 | 15 | 0 |
| 2001 | 25 | 6 |
| 2002 | 21 | 47 |
| 2003 | 12 | 48 |
| 2004 | 23 | 45 |
| 2005 | 20 | 59 |
| 2006 | 29 | 68 |
| 2007 | 18 | 59 |
| 2008 | 10 | 59 |
| 2009 | 16 | 71 |
| 2010 | 32 | 81 |
| 2011 | 24 | 86 |
| 2012 | 25 | 78 |
| 2013 | 28 | 78 |
| 2014 | 37 | 91 |
| 2015 | 39 | 90 |
| 2016 | 50 | 107 |
| 2017 | 64 | 93 |
| 2018 | 53 | 109 |
| 2019 | 54 | 110 |
| 2020 | 56 | 87 |
| 2021 | 45 | 103 |
| 2022 | 44 | 102 |
| 2023 | 40 | 87 |
| 2024 | 30 | 85 |
| 2025 | 41 | 94 |
| 2026 | 34 | 68 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- ß-amyloid cyclic ribonucleic acid, polypeptide, and application thereof6 Oct 2026US 12,753,215 B2
- Methods for identifying pre-disposition to cognitive decline and agents for reducing or preventing cognitive decline, or improving cognitive ability29 Sep 2026US 12,746,255 B2Societe des Produits Nestle S. A.
- Tau-binding antibodies29 Sep 2026US 12,747,288 B2Ucb Biopharma Srl
- Methods for apolipoprotein detection15 Sep 2026US 12,736,545 B2Biocross, S.L.
- Detection of beta amyloid protein as alzheimer's disease-causing factor in palatine tonsil and use thereof8 Sep 2026US 12,730,115 B2The Catholic University of Korea Industry-Academic Cooperation Foundation
- Tau assay8 Oct 2026US 2026/0309720 A1
- Early detection and monitoring of neurodegenerative diseases using a multidisease diagnostic platform8 Oct 2026US 2026/0309723 A1Durin Life Sciences, Inc.
- A nasal fluid sample comprising abeta, ptau and/or ttau8 Oct 2026US 2026/0309725 A1Noselab GmbH
- Hyperspectral Image-Guided Ocular Imager for Alzheimer's Disease Pathologies1 Oct 2026US 2026/0294329 A1Retispec Inc.
- Method for the in vitro diagnosis of a neurodegenerative disease1 Oct 2026US 2026/0298947 A1Institut National de la Sante et de la Recherche Medicale
Most cited
By later US patents
- Polypeptide marker for Alzheimer's disease and its use for diagnosis318US 4,666,829 AUniversity of California · 1987
- Methods for the detection of soluble .beta.-amyloid peptide244US 5,593,846 AAthena Neurosciences, Inc. · 1997
- Antibodies to A4 amyloid peptide174US 5,231,000 AThe McLean Hospital Corporation · 1993
- Methods for monitoring cellular processing of .beta.-amyloid precursor protein167US 5,441,870 AAthena Neurosciences, Inc. · 1995
- Methods of screening for compounds which inhibit soluble .beta.-amyloid peptide production152US 5,766,846 AAthena Neurosciences, Inc. · 1998